A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies Article

cited authors

  • Collier, Katharine A.; Valencia, Hugo; Newton, Herbert; Hade, Erinn M.; Sborov, Douglas W.; Cavaliere, Robert; Poi, Ming; Phelps, Mitch A.; Liva, Sophia G.; Coss, Christopher C.; Wang, Jiang; Khountham, Soun; Monk, Paul; Shapiro, Charles L.; Piekarz, Richard; Hofmeister, Craig C.; Welling, D. Bradley; Mortazavi, Amir

authors

Publication Date

  • January 25, 2021

webpage

published in

category

keywords

  • Histone deacetylase inhibitor
  • Neurofibromatosis type 2
  • Pharmacokinetics
  • Phase 1
  • Solid tumor

start page

  • 599

end page

  • 611

volume

  • 87

issue

  • 5